Novel genetic biomarkers for susceptibility to oral submucous fibrosis: Cytochrome P450 3A

被引:10
作者
Li, Ning [1 ]
Hu, Qiong [2 ]
Jiang, Canhua [1 ]
Hu, Yanjia [1 ]
Yuan, Yongxiang [1 ]
Jian, Xinchun [1 ]
Tang, Zhangui [1 ]
Guo, Feng [1 ]
机构
[1] Cent S Univ, Xiangya Hosp, Dept Oral & Maxillofacial Surg, Changsha 410008, Hunan, Peoples R China
[2] Second Peoples Hosp, Dept Pain Management, Changsha 410007, Hunan, Peoples R China
关键词
DRUG-INTERACTIONS; CYP3A5; METABOLISM; ETRAVIRINE;
D O I
10.1016/j.mehy.2011.07.049
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Oral submucous fibrosis (OSF) is a chronic and insidious oral mucosal disease, which always carries high risk of transition to oral cancer. Mainly based on genetic predisposition in pharmacokinetics for toxic substances of betel quid, there are obviously variable responses to betel quid among chewers. But the key genes resulting in interindividual variability in OSF development are still obscure. The cytochrome P450 3A (CYP 3A) gene family plays major roles in the oxidative metabolism of active endogenous and xenobiotic substrates, which is generally found polymorphic with variant alleles in different individuals and regarded as a major determinant of the interindividual variability in chemicals pharmacokinetics. Based on the specific property of CYP 3A, we consider this polymorphically expressed genotype could be a predictor of OSF susceptibility. Betel-quid chewers with lower level of CYP 3A expression might be more susceptible to toxicity of betel quid, resulting in higher risk of OSF lesion. Meanwhile, individuals at genetically high risk of OSF could be screened according to the genetic polymorphisms in some exclusive regions of the CYP 3A genes. By analyzing the polymorphisms of CYP 3A genes, we could differentiate interindividual variability for pharmacokinetics of betel-quid chewers, and then guide OSF therapy. (C) 2011 Published by Elsevier Ltd.
引用
收藏
页码:834 / 836
页数:3
相关论文
共 13 条
[1]   Luminogenic cytochrome P450 assays [J].
Cali, James J. ;
Ma, Dongping ;
Sobol, Mary ;
Simpson, Daniel J. ;
Frackman, Susan ;
Good, Troy I. ;
Daily, William J. ;
Liu, David .
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2006, 2 (04) :629-645
[2]   Clinical perspective on antiretroviral drug-drug interactions with the non-nucleoside reverse transcriptase inhibitor etravirine [J].
Kakuda, Thomas N. ;
Scholler-Gyure, Monika ;
Hoetelmans, Richard M. W. .
ANTIVIRAL THERAPY, 2010, 15 (06) :817-829
[3]   Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression [J].
Kuehl, P ;
Zhang, J ;
Lin, Y ;
Lamba, J ;
Assem, M ;
Schuetz, J ;
Watkins, PB ;
Daly, A ;
Wrighton, SA ;
Hall, SD ;
Maurel, P ;
Relling, M ;
Brimer, C ;
Yasuda, K ;
Venkataramanan, R ;
Strom, S ;
Thummel, K ;
Boguski, MS ;
Schuetz, E .
NATURE GENETICS, 2001, 27 (04) :383-391
[4]   Common allelic variants of cytochrome P4503A4 and their prevalence in different populations [J].
Lamba, JK ;
Lin, YS ;
Thummel, K ;
Daly, A ;
Watkins, PB ;
Strom, S ;
Zhang, J ;
Schuetz, EG .
PHARMACOGENETICS, 2002, 12 (02) :121-132
[5]   Discovery of novel biomarkers in oral submucous fibrosis by microarray analysis [J].
Li, Ning ;
Jian, Xinchun ;
Hu, Yanjia ;
Xu, Chunjiao ;
Yao, Zhigang ;
Zhong, Xiaohuan .
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2008, 17 (09) :2249-2259
[6]   CYP induction-mediated drug interactions:: in vitro assessment and clinical implications [J].
Lin, Jiunn H. .
PHARMACEUTICAL RESEARCH, 2006, 23 (06) :1089-1116
[7]   Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism [J].
Lin, YS ;
Dowling, ALS ;
Quigley, SD ;
Farin, FM ;
Zhang, J ;
Lamba, J ;
Schuetz, EG ;
Thummel, KE .
MOLECULAR PHARMACOLOGY, 2002, 62 (01) :162-172
[8]   MALIGNANT TRANSFORMATION RATE IN ORAL SUBMUCOUS FIBROSIS OVER A 17-YEAR PERIOD [J].
MURTI, PR ;
BHONSLE, RB ;
PINDBORG, JJ ;
DAFTARY, DK ;
GUPTA, PC ;
MEHTA, FS .
COMMUNITY DENTISTRY AND ORAL EPIDEMIOLOGY, 1985, 13 (06) :340-341
[9]   Two linked mutations in transcriptional regulatory elements of the CYP3A5 gene constitute the major genetic determinant of polymorphic activity in humans [J].
Paulussen, A ;
Lavrijsen, K ;
Bohets, H ;
Hendrickx, J ;
Verhasselt, P ;
Luyten, W ;
Konings, F ;
Armstrong, M .
PHARMACOGENETICS, 2000, 10 (05) :415-424
[10]  
PINDBORG J J, 1989, Annals Academy of Medicine Singapore, V18, P603